Novartis's meningococcal vaccine Menveo gets US complete response letter
02 July 2009
Katie McQue
Please Login to read the full article.
02 July 2009
Katie McQue
katie.mcque@informa.com
Novartis has received a complete response letter from the US FDA for the BLA of its investigational meningococcal conjugate vaccine Menveo.
In the letter, the agency has requested additional information on the clinical and the CMC (chemistry manufacturing and control) sections of the BLA....
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novartis's Bexsero MenB vaccine is immunogenic, but is it cost-effective?
- US FDA expands Sanofi's Menactra for use in toddlers, infants as young as 9 months
- WHO keen on meningitis vaccine as GSK makes EU filing
- Could Taiwanese breakthrough yield better synthetic meningococcal vaccines?
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
